MedPath

Comparison of DPP-4 inhibitors, vildagliptin and linagliptin in type2 diabetes

Not Applicable
Completed
Conditions
Type 2 diabetes mellitus
Registration Number
JPRN-UMIN000010445
Lead Sponsor
Yokohama City University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30) 5)pregnacy 6)Allergy for vildagliptin, linagliptin, repaglinide and glimepiride 7)Patients judged by the investigator to be ineligible for some other reason

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.